Search for a trial

A two-part, randomized, double-blind, placebo-controlled, single-center study to evaluate the safety and causal prophylactic efficacy of KAF156 in a controlled human malaria challenge model

This is a two part proof of efficacy study of KAF156 as a causal prophylactic agent in malaria. Results will be used to guide dose selection for further development of KAF156 in patients.

Safety and preliminary protective efficacy of genetically attenuated Pf*mei2 (GA2) malaria parasites in healthy Dutch volunteers

Phase 1 • Primary objective: to determine the safety and tolerability, including the attenuation phenotype of a novel late-arresting GAP, named GA2 parasite, administered by sequentially increasing numbers of mosquito bites.• Secondary objective: to…

Coadministration of genetically attenuated Plasmodium falciparum *mei2 (GA2) sporozoites with adjuvants - a proof of principle study

This study has been transitioned to CTIS with ID 2024-516488-99-00 check the CTIS register for the current data. Primary objectives: 1. To assess the effect of experimental immunization with GA2 sporozoites by mosquito bite with and without co-…

Safety and protective efficacy of genetically attenuated Pf*b9*slarp (PfSPZ-GA1) malaria parasites in healthy volunteers

The study is divided in Stage A and BGA1 stage A1. To determine the safety and tolerability of direct venous inoculation of PfSPZ-GA1 in healthy volunteers.GA1 stage B Primary objective:1. To determine the safety, and tolerability of PfSPZ-…